exRNAdisease

Entry Detail

---



General Information

Database ID: exR0088460 RNA Name: hsa-miR-432-5p RNA Type: miRNA Chromosome: chr14 Starnd: + Coordinate: Start Site(bp): 100884496 End Site(bp): 100884518 External Links: hsa-miR-432-5p

Disease Information

Disease Name: Breast Cancer Disease Category: Cancers MeSH ID: D001943 Type: Neoplasms/Breast Neoplasms Alias: Breast Neoplasms//Breast Neoplasm//Neoplasm, Breast//Breast Tumors//Breast Tumor//Tumor, Breast//Tumors, Breast//Neoplasms, Breast//Breast Cancer//Cancer, Breast//Mammary Cancer//Cancer, Mammary//Cancers, Mammary//Mammary Cancers//Malignant Neoplasm of Breast//Breast Malignant Neoplasm//Breast Malignant Neoplasms//Malignant Tumor of Breast//Breast Malignant Tumor//Breast Malignant Tumors//Cancer of Breast//Cancer of the Breast//Mammary Carcinoma, Human//Carcinoma, Human Mammary//Carcinomas, Human Mammary//Human Mammary Carcinomas//Mammary Carcinomas, Human//Human Mammary Carcinoma//Mammary Neoplasms, Human//Human Mammary Neoplasm//Human Mammary Neoplasms//Neoplasm, Human Mammary//Neoplasms, Human Mammary//Mammary Neoplasm, Human//Breast Carcinoma//Breast Carcinomas//Carcinoma, Breast//Carcinomas, Breast

Expression Detail

GEO ID: GSE101841 Description: Serum microRNA profile of Her2 positive metastatic breast cancer patients Experimental Design: Trastuzumab therapy Case Disease Type: Breast Cancer Case Disease SubType: HER2 positive metastatic breast cancer Case Sample: Breast Cancer Trastuzumab resistant Control Sample: Trastuzumab sensitive Number of Case: 42 Number of Control: 61 Number of Samples: 103

Regulatory Relationship

mRNA targets: Gene Symbol Chromosome Start Site(bp) End Site(bp) Strand ABL1 chr9 130713016 130887675 + ANXA2 chr15 60347134 60402883 - ATP5MC3 chr2 175176258 175184607 - BLCAP chr20 37492472 37527931 - CA12 chr15 63321378 63381846 - CALM1 chr14 90396502 90408268 + CELSR2 chr1 109249539 109275751 + CHTF8 chr16 69118010 69132578 - DNAJC13 chr3 132417502 132539032 + EPB41 chr1 28887091 29120046 + FADS2 chr11 61792980 61867354 + FN1 chr2 215360440 215436073 - GGA3 chr17 75236599 75262363 - GNAI2 chr3 50226292 50259362 + HMBOX1 chr8 28890395 29064764 + IGF1R chr15 98648539 98964530 + IPO9 chr1 201829149 201884291 + KDM3B chr5 138352685 138437028 + MFHAS1 chr8 8783354 8893630 - NAPEPLD chr7 103099776 103149560 - PHC3 chr3 170086732 170181749 - PRELID3B chr20 59033145 59042809 - PTCD3 chr2 86106223 86142157 + RASA1 chr5 87267883 87391931 + SETD7 chr4 139495941 139606699 - STAMBP chr2 73828916 73873659 + TMEM63A chr1 225845536 225882380 - TOB2 chr22 41433494 41446801 - ZBTB34 chr9 126860665 126885878 + ZNF12 chr7 6688433 6706947 - miRNA targets: NA circRNA targets: circRNA Symbol Chromosome Start Site(bp) End Site(bp) Strand hsa_circ_0001454 chr4 154524454 154533552 + hsa_circ_0001349 chr3 152132729 152150709 + lncRNA targets: lncRNA Symbol Chromosome Start Site(bp) End Site(bp) Strand AC009133.5 chr16 29808679 29812227 + AC016876.2 chr17 7581964 7584086 - AC068768.1 chr12 123262060 123262402 + AC239868.1 chr1 149861271 149862504 + KCNQ1OT1 chr11 2608328 2699994 - LINC00649 chr21 33915534 33977691 + NEAT1 chr11 65422774 65445540 + PCBP2-OT1 chr12 53464468 53465057 + SNHG16 chr17 76557764 76565348 + XIST chrX 73820649 73852723 - ZFAS1 chr20 49278178 49299600 + Display:

Experiment Detail

GEO ID: GSE101841 Sample Source: Blood Source Fraction: Serum Platform: GPL23138 Method: Microarray Num of detected RNA Type: 1 Num of detected RNAs of this Type: 1808 Sample treatment protocol: NA RNA Extract protocol: Total RNA was extracted from 103 samples with the Plasma RNA Purification Mini Kit (51000, NorgenBiotek Corporation, Canada), following manufacturer's instructions. RNA library preparation protocol: Total RNA extracted from 600ul serum was employed with 100 nmol/L of pCp-DY647 and 15 Units of T4 RNA ligase in a total reaction volume of 20 ul at 16°C overnight.

Reference

PMID: 29691399 Title: A serum microRNA signature predicts trastuzumab benefit in HER2-positive metastatic breast cancer patients. Author: Li H, Liu J, Chen J, Wang H, Yang L, Chen F, Fan S, Wang J, Shao B, Yin D, Zeng M, Li M, Li J, Su F, Liu Q, Yao H, Su S, Song E Journal: Nat Commun. 2018 Apr 24;9(1):1614. Description: MicroRNAs (miRNAs) have been used to predict therapeutic effects for various cancers, but whether miRNAs can serve as biomarkers for HER2+ metastatic breast cancer (MBC) patients remains unclear.